Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 4Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Male Urogenital Diseases 1Genital Diseases, Male 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1

Interventions

Trastuzumab 61Paclitaxel 57Cyclophosphamide 44pembrolizumab 35Fulvestrant 34Capecitabine 29Carboplatin 27Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 14durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × darolutamide × Clear all
NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

CellCentric Ltd.

Phase 1/2 Completed
220 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡